Duxin Sun

55PUBLICATIONS
97CO-AUTHORS
Separation technologiesBiologically active moleculesMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (55)

|Jul 05, 2026
Discovery of SD-2301 as a Highly Potent and Selective PROTAC STAT3 Degrader Capable of Achieving Complete Tumor Regression with Single Administration.

|Jun 23, 2026
Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancers.

|May 26, 2026
Machine Learning Model Predicts Clinical Adverse Events of Small Molecule Kinase Inhibitors in Cancer Patients Using On-/Off-Target Engagement and Tissue Selectivity.

|Apr 28, 2026
Dual targeting of PI3Kγ and STING overcomes regulatory B cell- and myeloid cell-driven immune suppression in pancreatic cancer.

|Mar 23, 2026
Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader.

Dimin Wu, Haibin Zhou, Longchuan Bai

|Mar 19, 2026
Albumin-Bound STING Agonist Reprograms HSPCs to Antitumor Neutrophils Enhancing CD8<sup>+</sup> T Cell Immunity.

Jinsong Tao, Hong-Yi Zhao, Chengyi Li

Pageof 10

Frequent Collaborators

25 joint publications

Shaomeng Wang

8 joint publications

Chao-Yie Yang

8 joint publications

Rohan Kalyan Rej

7 joint publications

Ranjan Kumar Acharyya